BR0101630A - Processo para a preparação do trihidrato do salmesilato de1-(4-hidroxifenil)-2(4-hidróxi-4fenilpiperidin-1-il)-1-propanol - Google Patents

Processo para a preparação do trihidrato do salmesilato de1-(4-hidroxifenil)-2(4-hidróxi-4fenilpiperidin-1-il)-1-propanol

Info

Publication number
BR0101630A
BR0101630A BR0101630-0A BR0101630A BR0101630A BR 0101630 A BR0101630 A BR 0101630A BR 0101630 A BR0101630 A BR 0101630A BR 0101630 A BR0101630 A BR 0101630A
Authority
BR
Brazil
Prior art keywords
phenylpiperidin
hydroxyphenyl
hydroxy
propanol
trihydrate
Prior art date
Application number
BR0101630-0A
Other languages
English (en)
Inventor
Joseph Philip Rainville
Terry Gene Sinay Jr
Stanley Walterwalinsky
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0101630A publication Critical patent/BR0101630A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)

Abstract

Patente de Invenção: "PROCESSO PARA A PREPARAçãO DOTRIHIDRATO DO SAL MESILATO DE1-(4-HIDROXIFENIL)-2-(4-HIDRóXI-4-FENILPIPERIDIN-1-IL)-1-PROPANOL". A presente invenção refere-se a um processo para apreparação do trihidrato do mesilato do(1S,2S)-1-(4-hidroxifenil)-2-(4-hidróxi-4-fenilpiperidin-1-il)-1-propanoltendo a fórmula (I): A presente invenção também refere-se aindaum processo para a resolução enantiomérica e isolamento do salD-(-)-tartarato do composto de fórmula (I).
BR0101630-0A 2000-04-28 2001-04-27 Processo para a preparação do trihidrato do salmesilato de1-(4-hidroxifenil)-2(4-hidróxi-4fenilpiperidin-1-il)-1-propanol BR0101630A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20067300P 2000-04-28 2000-04-28

Publications (1)

Publication Number Publication Date
BR0101630A true BR0101630A (pt) 2001-12-04

Family

ID=22742684

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0101630-0A BR0101630A (pt) 2000-04-28 2001-04-27 Processo para a preparação do trihidrato do salmesilato de1-(4-hidroxifenil)-2(4-hidróxi-4fenilpiperidin-1-il)-1-propanol

Country Status (27)

Country Link
US (1) US6645986B2 (pt)
EP (2) EP1151995B1 (pt)
JP (2) JP3615496B2 (pt)
KR (1) KR100442718B1 (pt)
CN (2) CN1590373A (pt)
AR (1) AR028376A1 (pt)
AT (1) ATE277014T1 (pt)
AU (1) AU781436B2 (pt)
BR (1) BR0101630A (pt)
CA (1) CA2345582C (pt)
CZ (1) CZ20011471A3 (pt)
DE (1) DE60105689T2 (pt)
DK (1) DK1151995T3 (pt)
ES (1) ES2227071T3 (pt)
HK (1) HK1040246B (pt)
HU (1) HUP0101723A3 (pt)
ID (1) ID30006A (pt)
IL (1) IL142705A0 (pt)
IN (1) IN191027B (pt)
PL (1) PL347298A1 (pt)
PT (1) PT1151995E (pt)
RU (1) RU2203888C2 (pt)
SI (1) SI1151995T1 (pt)
TR (1) TR200402696T4 (pt)
TW (1) TW200505858A (pt)
YU (1) YU27701A (pt)
ZA (1) ZA200103320B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1311839B1 (en) * 2000-06-21 2006-03-01 Bioarray Solutions Ltd Multianalyte molecular analysis using application-specific random particle arrays
US6743921B2 (en) 2002-01-24 2004-06-01 Dsm Catalytica Pharmaceuticals, Inc. Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
US7754500B2 (en) 2003-11-21 2010-07-13 Anp Technologies, Inc. Asymmetrically branched polymer conjugates and microarray assays
DE602006019709D1 (pt) 2005-05-02 2011-03-03 Anp Technologies Inc

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199800208T1 (pt) * 1995-08-11 1998-05-21 Pfizer Inc.

Also Published As

Publication number Publication date
JP3615496B2 (ja) 2005-02-02
EP1151995A1 (en) 2001-11-07
CN1321638A (zh) 2001-11-14
US6645986B2 (en) 2003-11-11
HUP0101723A3 (en) 2003-03-28
ID30006A (id) 2001-11-01
DE60105689T2 (de) 2005-11-10
JP2004196823A (ja) 2004-07-15
IN191027B (pt) 2003-09-13
CA2345582A1 (en) 2001-10-28
DK1151995T3 (da) 2004-12-13
PL347298A1 (en) 2001-11-05
SI1151995T1 (en) 2004-12-31
HK1040246B (zh) 2005-10-28
CA2345582C (en) 2006-05-30
CN1210262C (zh) 2005-07-13
ZA200103320B (en) 2002-10-24
US20020016465A1 (en) 2002-02-07
HK1040246A1 (en) 2002-05-31
AU3889601A (en) 2001-11-01
ATE277014T1 (de) 2004-10-15
EP1477479A1 (en) 2004-11-17
KR20010098960A (ko) 2001-11-08
AR028376A1 (es) 2003-05-07
JP2001354651A (ja) 2001-12-25
HU0101723D0 (en) 2001-07-30
PT1151995E (pt) 2004-11-30
RU2203888C2 (ru) 2003-05-10
IL142705A0 (en) 2002-03-10
ES2227071T3 (es) 2005-04-01
CN1590373A (zh) 2005-03-09
DE60105689D1 (de) 2004-10-28
EP1151995B1 (en) 2004-09-22
TR200402696T4 (tr) 2004-11-22
AU781436B2 (en) 2005-05-26
HUP0101723A2 (hu) 2002-02-28
YU27701A (sh) 2003-04-30
CZ20011471A3 (cs) 2002-02-13
TW200505858A (en) 2005-02-16
KR100442718B1 (ko) 2004-08-02

Similar Documents

Publication Publication Date Title
CA2545503C (en) Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseases
AR040661A1 (es) Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2
BR9909844A (pt) Processo para sintetizar um composto, e, composto.
FI20031369A (fi) 4-[4-dimetyyliamino-1-(4'-fluorifenyyli)-1-hydroksibutyyli]bentsonitriilin diastereomeerinen suola
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
BR0108893B1 (pt) composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos.
BRPI0411268A (pt) processo para a preparação de um composto 3-aril butil-amina substituìdo
EA200400140A1 (ru) Пероральные противодиабетические агенты
BR9909739A (pt) Benzotiadiazóis e derivados
BR0016087A (pt) Processo para a formação de um grupo de mono-fosforila primária em uma funcionalidade de 1,2-diol-propanóila terminal, processos para a preparação de 5-(het-x-metil)-3-(4-(1-benzil-1,2,5,6-tetraidropirid-4-il)- 3,5-difluorofenil)oxazolidin-2-ona, e de 5-isoxazol-3-iloximetil-3-(4-(1-benzil-1,2,5,6-tetraidrop irid-4-il)-3,5-difluorofenil)oxazolidin-2-ona, e, composto intermediário quìmico
BR0101630A (pt) Processo para a preparação do trihidrato do salmesilato de1-(4-hidroxifenil)-2(4-hidróxi-4fenilpiperidin-1-il)-1-propanol
HK1055741A1 (en) A pyridine-1-oxide derivative, and process for itstransformation into pharmaceutically effective co mpounds
WO2005123670A3 (en) Crystalline form of a substituted pyrrolidine compound
BR0111472A (pt) Processo para a preparação de um composto, composto, e, forma polimórfica de um composto
KR930010047A (ko) 아미노알칸포스핀산 및 이의 염
PE20050440A1 (es) Derivados de n-heterociclo sustituidos para modificar la recaptacion de monoaminas
BR0113259A (pt) Processo para a preparação de um composto, composto e processo para a preparação de compostos
BRPI0411293A (pt) composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto
EP1253139A3 (en) Multioligoanilinated fullerenes
BRPI0508808A (pt) processo quimio-enzimático para preparar escitalopram
BR9610175A (pt) Composto processo de preparação do composto composição farmacêutica e utilização do composto
BR0116721A (pt) Processo para a preparação de (±)-trans-4-p-fluorofenil-3-hidroximetil-1-metilpiperi dina
BR0101611A (pt) Processo para a preparação do sal mesilato tri-hidrato de 1-(4-hidroxifenil)-2-(4-hidróxi-4-fenilpiperidin-1-il)-1-propanol e in-termediários úteis para esse processo
BR9808574A (pt) Processo para a fabricação de um composto racêmico, composto, e, intermediários dos produtos preparados.
BR0112849A (pt) Processo para a preparação de um composto quiral, e, composto quiral

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7O E 8O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2012 DE 28/07/2009.